HEALTHSTAT NEWS
HHS confirms Americans with high-risk Ebola exposures will have access to experimental therapy
HHS confirms Americans with high-risk Ebola exposures in Central Africa will receive access to an experimental antibody treatment, MBP-134, developed by Mapp Biopharmaceuticals with funding from the Biomedical Advanced Research and Development Authority. The treatment has shown promise in animal testing but has not yet been clinically proven effective in humans.
Mentioned
Related Signal
Adjacent reporting
- STAT+: Regenxbio says Duchenne gene therapy succeeded in clinical trial, paving way for FDA submission
- Supercharging Immune Cells May Help Control HIV Long-Term
- Ebola vaccine for Bundibugyo strain could take months before human trials
- Tools to fight hantavirus show promise despite limited funding. Now researchers hope to continue
- Pancreatic cancer: Dr. Pudlarz praises 'new generation targeted therapy' that inhibits gene mutation
- Vaccination generates broadly cross-neutralizing antibodies to the HIV Env apex